Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...

Pfizer said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting ...

Pfizer Inc.’s stock was rallying Tuesday after the drug giant lifted its 2025 adjusted profit estimate, on the heels of a 10% ...

Pfizer stock rises after a strong Q2, boosted by cost savings, pipeline progress, and an upgraded 2025 profit outlook.

Investor sentiment has been adversely affected by worries regarding the company’s drug pipeline. Nonetheless, we believe PFE ...

The controversial move affects development of vaccines against COVID-19, flu and H5N1, drawing criticism from public health ...

Pfizer (NYSE:PFE) stock gains as the company surpasses Q2 2025 expectations with $14.7B revenue and raises its full-year ...

Pfizer ( PFE) reported a beat in second quarter earnings Tuesday, and reaffirmed its 2025 guidance of between $61 to $64 ...

Bourla, who took over as CEO in 2019, has declined to say how long he intends to remain in his role at Pfizer. Developing a ...

COVID questions answered. I just participated in a classic disease spreader: We had a family reunion with over 30 people. One ...

In the second quarter, Pfizer reported adjusted diluted earnings per share of $0.78 on revenue of nearly $14.7 billion. Both ...